GLP-1 Depression: Can These Medications Cause or Worsen It?

Thinking about suicide or hurting yourself? In the U.S., call or text 988 to reach the Suicide & Crisis Lifeline. It's free, it's open 24 hours, and you do not have to be in immediate danger to use it. If you are in immediate danger, call 911 or go to the nearest emergency room.

By the Weight Loss Provider Guide Research Team · Last verified: August 6, 2026
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. No provider is recommended anywhere on this page, and no company paid to influence anything you're about to read. This page explains published evidence; it does not diagnose a mood disorder or tell you to start, stop, or change a prescription.

The short answer

GLP-1 depression has not shown up as an increased population-level risk in the largest FDA review. On January 13, 2026, the FDA reported a review of 91 placebo-controlled trials covering 107,910 people. It found no increase in suicidal thoughts or behavior — or in depression, anxiety, irritability, or psychosis. The FDA then asked the makers of Wegovy, Zepbound, and Saxenda to remove the suicide warning from their labels. Current U.S. prescribing information shows that the warning was removed from all three. 1 2 3 4

But here's the part almost nobody tells you: that's the answer for a crowd of 107,910 people. It is not the answer for you.

And there's a detail buried in the labels that explains this whole mess. Ozempic's diabetes label did not carry that weight-loss warning. Wegovy's did. Same active ingredient. Different brand and indication.

We'll show you why in a minute. First, the thing that matters most.

Start here: how urgent is this?

Find your row. Everything else on this page can wait until you've read it.

📋 Build your GLP-1 mood timeline — free, no email

Put your dose dates and your symptoms into one clear note you can hand to your prescriber. It takes about two minutes.

Build my mood timeline →

It won't diagnose you. It won't tell you to change your dose. It just organizes what you already know into something a clinician can actually use.

What does the evidence say about GLP-1 depression?

The strongest evidence available says there is no increased risk across a population. The FDA reviewed 91 placebo-controlled trials with 107,910 participants — 60,338 on a GLP-1 medicine and 47,572 on placebo — and found no increase in suicidal behavior or in psychiatric events including depression and anxiety. A separate FDA study of 2,243,138 people found no increase in intentional self-harm compared with SGLT2 inhibitors. Neither finding proves that a specific person's mood change is unrelated to their medicine. 1

Let's be precise about what "no increased risk" means, because both sides of the internet get this wrong.

It means researchers took a large group of people on a GLP-1 medicine and a comparison group, and the studied outcomes did not show up more often in the GLP-1 group. On average. Across a lot of people.

It does not mean nobody ever feels different on these drugs. Averages hide individuals. A medicine can leave 99 people unchanged and still be part of what's happening to the hundredth.

Here is the FDA's exact population-level conclusion: the trial results "did not show an increased risk for SI/B or for other relevant psychiatric adverse events such as anxiety, depression, irritability, or psychosis." 1

Depression is named. Directly. That's the strongest population-level answer that currently exists.

The honest limit — and we'd rather say it out loud

We cannot tell you whether your medicine caused your mood change. Neither can any other website. Any page that claims it can is guessing.

That's not a dodge. It's the actual state of the evidence, and there are two reasons for it.

First, population studies measure averages, not people. Second — and this one matters more than it gets credit for — the big weight-loss trials often excluded people at the highest psychiatric risk.

The STEP semaglutide trials excluded people with major depressive disorder within the prior two years, certain severe psychiatric disorders, a PHQ-9 depression score of 15 or higher, a lifetime suicide attempt, or recent suicidal thoughts with intent or a plan. The later psychiatric analysis covered 3,681 adults and found no increase in depression scores or suicidal thoughts or behavior compared with placebo. 7

That is reassuring for people who looked like the trial participants. It does not answer every situation. If you had recent major depression, severe mental illness, a lifetime suicide attempt, or recent suicidal intent, the STEP data do not describe your risk well. A past history of depression did not automatically exclude every participant, so it is also too broad to say the trials tell us nothing about anyone who has ever had depression.

What we can do is show you which explanations fit your timeline and which don't. That's usually enough to turn a frustrating appointment into a useful one.

Then why did I read that GLP-1s raise depression risk by 195%?

Because that study is real — and it compared GLP-1 users with matched people who were not prescribed a GLP-1. A 2024 analysis in Scientific Reports matched 162,253 GLP-1 users with 162,253 nonusers and reported a 195% higher rate of recorded major depression. Studies that used placebo or another diabetes drug as the comparison usually found no difference, a much smaller difference, or a lower risk. The comparison group, the people included, and the definition of "depression" explain much of the disagreement. 11

This is the part of the story nobody assembles for you. So we did.

The design decoder: ten studies, three questions

Before you read any GLP-1 depression study, ask three things. You can often understand why the estimates differ before you reach the headline.

1. Who was in it? People who already had depression? People who didn't? People with higher-risk histories deliberately excluded?
2. Who were they compared with? Placebo, another diabetes medicine, or people not prescribed a GLP-1?
3. What counted as depression? A diagnosis code, a new antidepressant, a questionnaire score, self-harm, or a hospital event?

Now look at what happens.

Now read the pattern

Line those studies up by who they compared people with and the noise starts to make sense.

• Compared with placebo in a trial? No overall increase. Several analyses say the same thing, although they reuse some of the same underlying trials and should not be counted as fully separate crowds.
• Compared with another diabetes drug? No large signal. The FDA Sentinel study found nothing. The Medicare study found no significant difference versus SGLT2 inhibitors and a modestly lower risk versus DPP-4 inhibitors. Chang found a small increase versus SGLT2 inhibitors.
• Compared with people not prescribed a GLP-1? That is where the 195% figure comes from.
• Looked only at people who already had depression or anxiety? The Swedish within-person study found lower rates of worsening during semaglutide and liraglutide use, but not with exenatide or dulaglutide.

Why can a nonuser comparison make the number larger? Because people who receive a GLP-1 prescription can differ from people who do not in ways a database cannot fully erase. They may have different illness severity, health-care contact, screening, weight history, or treatment goals. More visits and more questions can also create more diagnosis codes.

A new diagnosis code is not always the same thing as a new illness beginning that day. It can represent a new illness, an old problem finally recorded, or both. That distinction is doing enormous work in the 195% figure, and most social posts never mention it.

Then there is the last large cohort, which flips the direction. It studied people who already had depression or anxiety — a group underrepresented in many trials — and found lower rates of worsening during semaglutide and liraglutide use. Only two of the four drugs showed a statistically significant association. That argues against turning the result into a simple class-wide promise.

The most honest number on this whole page

A 2025 systematic review pooled four studies and got a risk estimate of 0.568 — which sounds reassuring until you see the uncertainty around it. The 95% confidence interval was 0.077 to 4.205. The prediction interval ran from 0.001 to 218.938. 13

That's not a number you should use to make a personal decision. It is a measurement of how badly the included studies disagreed.

Here's the plain version: these studies are not all answering the same question, and everyone online is quoting them as if they are.

Why did the warning exist in the first place?

The warning followed the weight-loss indication, not every U.S. label for the same active ingredient. Wegovy and Ozempic both contain semaglutide. Wegovy's weight-management label carried the warning; the diabetes-use GLP-1 labels did not. The same label split existed for Zepbound and Mounjaro, and for Saxenda and Victoza. The FDA says the weight-loss warning was included because similar language appeared on other weight-loss medicines and was based on reports with older drugs used or studied for weight loss — not because the FDA had found a GLP-1 trial signal. 1

This is the fact that reframes the entire question, and we haven't found it assembled anywhere else. You can check it yourself in about five minutes.

Same active ingredient. Different label history.

Read that table again. A molecule-level effect would be expected to matter across brands, but brand dose, population, and use can differ. The label split does not prove that an individual could never have a mood change. It tells you why the old warning cannot be treated as proof that Wegovy, Zepbound, or Saxenda had shown a depression signal while the diabetes brands had not.

The FDA said why the warning was there: similar language was already used on other weight-loss products.

So what did those older warnings look like?

What the older weight-loss warnings actually looked like

These are examples of the older weight-loss labeling landscape. The FDA did not say that one named drug directly caused the wording on every GLP-1 label.

There it is. Contrave carries a boxed warning because it contains an antidepressant. Qsymia carries a warning tied to topiramate and the antiepileptic class. Rimonabant had a different mechanism and a real psychiatric safety problem.

The GLP-1 warning followed weight-loss labeling practice. It was not generated by a GLP-1 trial signal at approval.

That's not a conspiracy. It's how a precaution can begin broad and then narrow as evidence grows. The part worth being angry about is simpler: a lot of people saw the warning and reasonably assumed it meant the GLP-1 itself had already been shown to cause the problem. The FDA's final review says that is not what the evidence showed.

Why does my box still say it, then?

Because official label revisions and printed materials do not all change on the same day. The FDA requested removal in January 2026. Zepbound and Saxenda list the removal in February 2026. A printed Medication Guide, carton, or pharmacy handout from older stock may still show the prior language. You can check the current electronic label yourself in under a minute. 1 3 4

How to check your own medicine's current label:

1. Go to DailyMed — the U.S. National Library of Medicine's official label database. It is free and needs no account.
2. Search your brand name: Wegovy, Zepbound, Ozempic, or whatever you take.
3. Open the label and look for "Recent Major Changes."
4. If a section was removed, the label should list the removal and month.

That's it. You are looking at the current electronic prescribing information, not a screenshot from an old article.

One thing we found while doing this, and we're saying it out loud: Novo Nordisk's current Wegovy prescribing-information PDF lists removal as 01/2026. DailyMed lists it as 02/2026. We found no public explanation for the one-month difference. Zepbound and Saxenda both list 02/2026. 2 3 4 5

It changes nothing about the FDA's conclusion or the fact that the section is gone. We're telling you because we'd rather show you a small mismatch than pretend every official page lines up neatly.

Six things worth checking if you feel flat on a GLP-1

Feeling numb, joyless, tired, or unmotivated on a GLP-1 can come from several things that overlap. The medicine may be part of the timing. So may eating much less, dehydration, another health problem, a change in how you use food or alcohol, a different medicine, or depression that needs care in its own right. A website cannot sort those apart from symptoms alone.

This is the section we'd want if it were us. Find the row that sounds closest, then bring the whole pattern to your prescriber.

The one question that does most of the work

Did this begin after you started the medicine or after a dose change?

If yes, write down the exact dates. Timing is useful. It is not proof. Dose changes can also change nausea, food intake, fluid intake, sleep, blood sugar, and other medicines' effects.

Then ask the second question: What else changed in the same week? A new prescription, illness, bad sleep, a life event, less alcohol, more vomiting, or much less food can matter as much as the injection date.

If it came on slowly over months, a clinician may look harder for a medical, nutritional, sleep, or mental-health cause. If it does not track the medicine cleanly, that still does not rule the medicine in or out.

About number four

We want to spend a second here, because it's the one people are embarrassed to say out loud.

For a lot of people, food was the most reliable good thing in the day. Not a moral failure. Not a lack of discipline. Just the thing that was always there and always delivered.

Then the medicine turns the volume down on that. Many people describe it as relief — the food noise finally stops. But if food was carrying more weight than you realized, quieting it can leave a gap where something used to be. And nothing automatically moves in to fill it.

That's a real loss. It can feel like flatness. Rebuilding pleasure, routine, movement, people, or other rewards may help. But if the numbness spreads beyond food, lasts, or starts affecting daily life, do not explain it away as a lifestyle problem. Tell someone.

📋 Your two minutes, your timeline

You've just read six possible explanations. The one that fits you depends heavily on your dates — when you started, when your dose changed, when the mood shifted, and what else changed.

Build my timeline below →

Nothing is stored. It does not diagnose. It gives you a cleaner note to bring to care.

Should I stop taking it?

Do not make a dose change on your own. Contact the prescriber who manages the medicine. If you're having thoughts of harming yourself or cannot stay safe, that is an urgent call, not a next-appointment conversation. For everything else, there are real options between "keep going exactly as-is" and "quit."

Almost everyone treats this as a switch. It isn't. Here is the actual menu a prescriber may work from:

We found no trial that compares these mood-management choices head-to-head. No study has tested "delay the increase" against "step back" for a GLP-1-related mood complaint. This is a judgment call made by a clinician who knows your history — which is exactly why we can't make it for you and why anyone online who tries is overstepping.

Changing the medicine, food, sleep, and other prescriptions all at once can make the pattern harder to read. A clinician-guided plan gives you a better chance of learning what helped while keeping the safety problem first.

If you're worried they'll take you off it and you don't want that, say so directly. Something like:

"This medicine is helping me and I don't want to lose that. I also don't want to ignore how I've been feeling. Can we look at the safest options before we decide anything?"

That sentence changes the conversation. It tells your prescriber you're a partner, not a problem.

Can I take a GLP-1 with my antidepressant?

Taking an antidepressant is not an automatic reason you cannot use a GLP-1. Current Wegovy and Zepbound labels do not list a blanket contraindication with SSRIs or antidepressants. They do say these medicines delay stomach emptying and may affect oral-drug absorption. Both labels tell clinicians to consider closer monitoring for oral medicines with a narrow therapeutic index or medicines that already require level checks. Lithium deserves special attention. Published cases describe lithium toxicity after semaglutide and after a switch to tirzepatide. 2 3 17 18

This section is the one we'd most want you to read if you take psychiatric medication, because the answer is not a universal interaction checker. It is a medication-list problem.

The lithium finding

Two reports, both peer-reviewed:

Three-patient semaglutide case series. Three people taking lithium started semaglutide. Two developed lithium toxicity. In the third case, clinicians lowered lithium in advance and still needed close monitoring. The authors could not prove one mechanism and pointed to several possibilities, including reduced intake, dehydration from vomiting or diarrhea, kidney changes, and delayed stomach emptying. 17

A tirzepatide case report. A 23-year-old with schizoaffective disorder developed lithium toxicity after changing from semaglutide to tirzepatide. A single case cannot establish a rate, but it adds a reason to monitor when starting, changing, or switching these medicines. 18

Nobody has pinned down one mechanism. That is why the action is monitoring, not guessing.

What matters is that lithium is checkable with a blood test. If you take it, ask the clinician who manages your lithium and the clinician prescribing the GLP-1 for one shared plan. That plan may include a baseline lithium level and kidney function, a repeat level after starting, switching, or changing the GLP-1 dose, and an earlier check if you have vomiting, diarrhea, low fluid intake, dehydration, illness, or new toxicity symptoms. Do not change lithium on your own.

What the labels themselves say

Zepbound's prescribing information says to monitor oral medicines with a narrow therapeutic index — the term for a drug where the gap between a helpful amount and a harmful amount is small — and gives warfarin as an example. Wegovy says to consider increased clinical or laboratory monitoring for medicines with a narrow therapeutic index or medicines that require monitoring. 2 3

Lithium is not named in either GLP-1 label. The case reports are the reason it gets its own section here.

The quieter finding: who got left out of the trials

Here is something we pulled from the trial protocols themselves.

The main tirzepatide obesity trial, SURMOUNT-1, excluded people who had recently used eleven named psychiatric medicines: imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproate, and lithium. The protocol allowed SSRIs other than paroxetine. STEP 1 did not use that same eleven-drug list, although it had its own psychiatric exclusion criteria. 23

Sit with that for a second. If you take lithium, valproate, certain antipsychotics, or one of those named antidepressants, the main tirzepatide weight-loss trial gives less direct evidence about people in your situation.

That's not proof of an interaction and it is not wrongdoing. Several of those medicines can affect weight, which could muddy a weight-loss trial. But it is an honest reason not to pretend the trial answered every psychiatric-medication question.

Quick reference

There is no universal "safe with all antidepressants" answer, and we're not going to invent one. The answer depends on the exact medicine, dose, health history, symptoms, and what else is going on.

I already have depression. Can I still start a GLP-1?

Yes — depression itself is not listed as a contraindication for Wegovy or Zepbound. Their listed contraindications are a personal or family history of medullary thyroid cancer, a rare genetic condition called MEN 2, and a prior serious allergic reaction to the medicine or its ingredients. Depression still belongs on the intake form because it affects screening, follow-up, and what changes should trigger a call. 2 3

Let's use this. The trial exclusion criteria we mentioned earlier are actually a useful rubric for judging a telehealth program.

Researchers running the STEP trials screened for recent major depression, severe psychiatric conditions, depression scores, and suicide history. They screened because those details mattered enough to affect who entered the study.

So here's a fair question to ask of any program: if a clinical trial thought this was worth asking, why didn't your intake form?

What good screening looks like

A program that's taking you seriously will:

• Ask about mental health history on intake, not just physical health
• Ask what medications you take — all of them, including psychiatric ones
• Give you a way to reach a clinician between refills, not just a chatbot
• Tell you what to do if something changes
• Have someone who will actually read your answer if you write, "I've been feeling off"

A program that asks nothing isn't being convenient. It's being thin. That's a fair thing to weigh when you're choosing where to go — and it's a much better filter than price alone.

What to set up before you start

Ten minutes now saves you a lot of guessing later. Write down:

• Your mood on an ordinary day
• Your sleep
• Your energy
• What you currently enjoy — hobbies, people, work, anything
• Every medication you take
• Any past stretch where things got bad, and roughly when
• Who you will contact if your mood changes between visits

That's your baseline. If something shifts in month three, you'll have something to compare it with instead of trying to remember how you felt in the spring.

One thing we'll say plainly: if you're in a mental health crisis now, handle the crisis first and contact the prescriber before starting a new medicine. The GLP-1 decision can wait until you are safe.

Is one GLP-1 safer for mood than another?

Nobody can rank them honestly, because we found no head-to-head trial designed to compare GLP-1 medicines for mood safety. The useful signal comes from the Swedish study of people who already had depression or anxiety: semaglutide and liraglutide were associated with lower risk of worsening, while exenatide and dulaglutide were not significantly associated either way. That's a signal worth knowing, not a ranking you should shop from. 12

We're not going to build you a "best GLP-1 for depression" table. It would be the single most misleading thing we could publish, and it would be based on nothing.

What we can give you is the actual label and evidence comparison, with the limits attached.

A note on the language: tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it works on two hormone pathways instead of GLP-1 alone. Most people group it with GLP-1 medicines in conversation, and we do too — but studies of semaglutide do not automatically prove the same result for tirzepatide.

And a word about compounded products

We have to say this clearly because we're a comparison site and it's uncomfortable.

Compounded semaglutide and compounded tirzepatide are not FDA-approved products and do not have an FDA-approved prescribing label of their own. FDA does not review a compounded drug for safety, effectiveness, or quality before it is marketed. 21

That means the label history on this page — the warning going on an approved brand and coming off in 2026 — is not a label history for a compounded vial. The FDA's 91-trial review is strong evidence about the GLP-1 development programs it reviewed. It does not prove that every compounded formulation has the same contents, quality, exposure, or risk as an approved product.

That's a real gap in the evidence, and it applies to mood the same way it applies to everything else. A page that calls a compounded product "the same as" an approved brand is extending evidence past where it goes.

Read our separate guide: Is compounded semaglutide safe?

Do GLP-1s actually help depression? I read that too

Some early evidence points that way, but no GLP-1 is approved to treat depression and nobody should start one for that reason. The largest real-world study here found that, among people who already had depression or anxiety, semaglutide use was associated with a 42% lower rate of worsening mental illness. A small randomized trial of 72 adults found oral semaglutide changed performance on an effort-based motivation task. Both are signals to study, not proof of an antidepressant effect. 12 19

You've probably seen headlines going the other direction from the scary ones. Here's what's actually behind them.

The Swedish national study. It included 95,490 people with depression or anxiety who were also using diabetes medicines. During semaglutide use, the adjusted hazard ratio for worsening mental illness was 0.58. During liraglutide use, it was 0.82. Because this was observational and compared periods within people's real lives rather than assigning treatment at random, it shows an association, not causation. 12

A small randomized trial. Seventy-two adults with major depressive disorder and a BMI of 25 or higher were followed for 16 weeks. Oral semaglutide increased effort for high-value rewards on a laboratory task. That is interesting. It is not the same as showing that depression went into remission, and the trial does not make semaglutide an antidepressant. 19

There are plausible explanations for better mood outcomes that do not require a direct antidepressant effect. Weight change, blood sugar, sleep, physical function, health contact, hope, and treatment support can all move at the same time.

The honest position: researchers are genuinely investigating whether GLP-1 pathways affect mood, reward, and motivation. It's interesting. It's early. Do not swap your antidepressant for a weight-loss medicine, and do not let anyone sell you one as depression treatment.

What happens to my mood if I stop?

There is no reliable mood timeline that applies to everyone, and stopping on your own is not a clean test of causation. A 2026 observational study found that depressive-disorder rates after stopping a GLP-1 were similar to rates after stopping DPP-4 or SGLT2 medicines, while anxiety-disorder rates were modestly higher after GLP-1 cessation. That is a reason to plan follow-up, not proof of withdrawal. 20

This is the newest and thinnest part of the evidence, so we'll be careful with it.

What we know about weight: regain after stopping is common. In the STEP 1 extension, participants regained about two-thirds of the weight they had lost during the year after semaglutide was withdrawn. That does not tell us what any one person's mood will do, but the return of appetite, weight concern, or food noise can be distressing on its own. 22

What the 2026 study found: researchers used health records from people with type 2 diabetes and compared outcomes after GLP-1 treatment ended with outcomes after other diabetes medicines ended. Depression rates were similar across the comparisons. Anxiety rates were higher after GLP-1 cessation. The study was observational, so it cannot prove a withdrawal effect, and a diabetes population may not look like a weight-management population. 20

What it means practically: if you and your prescriber decide to stop, don't treat that as the end of the conversation. Set a check-in. Watch mood, sleep, appetite, eating, and how you are functioning. The mistake isn't asking whether stopping is right. It is changing treatment and then having no plan for what happens next.

What do I actually say to my prescriber?

Bring dates, not impressions. "I've been feeling off lately" gives a clinician almost nothing to work with. "I started in March, changed dose on June 10, and stopped enjoying anything around June 20" gives them a pattern they can investigate.

Copy this. Fill in the blanks. Read it out loud or hand it over.

"I started [medicine] on [date]. My dose changed on [date]. Around [date], I noticed [what changed]. It's affecting my [sleep / work / relationships / eating / daily life]. I am / am not having thoughts of harming myself. Other things that changed around the same time: [medications, sleep, eating, illness, alcohol or cannabis, life events]. Can we look at whether this might be the medicine, my eating or fluids, another medication, depression, or something else — and decide what's safest?"

Then ask these:

• Could another health problem or another medicine explain this?
• Does the timing after starting or changing the dose matter?
• What symptoms mean I should call you right away instead of waiting?
• Should we delay the next dose increase while we sort this out?
• Would blood work help in my case — such as a blood count, iron, B12, thyroid, kidney function, glucose, or a lithium level?
• Would it help to talk to a mental health clinician too?
• Who do I contact if this gets worse on a weekend?

And if you're scared they'll pull the prescription, put that on the table too. Clinicians are far more likely to work with you than against you when you say what you're actually worried about.

Build your GLP-1 mood timeline

This is the tool the rest of the page has been pointing to. Copy it into your notes app, fill it out, and take it to the person managing your prescription. It stores nothing because it never leaves your device.

Are you thinking about hurting yourself, or are you unsure you can stay safe? Stop the worksheet. Call or text 988 now. Call 911 or go to an emergency room if the danger is immediate.

Two-minute version

• Medicine and brand:
• Why I take it:
• Start date:
• Current dose:
• Dose-change dates:
• Mood or behavior change:
• First date I noticed it:
• What it is affecting:
• Thoughts of self-harm: yes / no / not sure
• Food and fluid change:
• Nausea, vomiting, or diarrhea:
• Sleep change:
• Other medicines or supplements changed:
• Alcohol, cannabis, or nicotine changed:
• Illness or major life event around the same time:
• Who I will call if it gets worse:

One-line timeline

The sentence to put at the top

"The change I most need help with is ________. It started around ________. It is affecting ________."

That is enough. You do not need to solve the cause before you ask for help.

What we actually verified

We think you should be able to see our work. Here is what we checked, what each source can prove, and where the evidence stops.

The one unresolved label detail

Wegovy's warning-removal month. Novo Nordisk's current PDF lists 01/2026. DailyMed lists 02/2026. Both agree the section was removed. We found no public explanation for the date mismatch. 2 5

What we did not do

We did not examine anyone. We did not review anyone's chart. This page has no medical reviewer, and we're not going to put a badge on it pretending otherwise. It's research — sourced and checkable — but it is not medical advice and it cannot replace someone who knows your history.

What we deliberately did not claim

• That a GLP-1 can never contribute to an individual person's mood change
• That GLP-1 medicines treat depression
• That any brand is the "safest for mood"
• That compounded products carry the same evidence as approved products
• That an online worksheet can diagnose depression
• That you should change or stop treatment based on this page

Common questions

Does Ozempic cause depression?

The strongest population evidence has not found an increased depression risk. Ozempic's diabetes label also did not carry the weight-management suicide warning addressed by the FDA in 2026; Wegovy's did, even though both contain semaglutide. That label history does not cancel an individual symptom. Tell your prescriber if your mood changed. 1

Does Wegovy cause depression?

The FDA's 2026 review found no increased risk across trial populations. It reviewed 91 trials and found no increase in depression, anxiety, irritability, psychosis, or suicidal thoughts or behavior. Wegovy's warning was then removed. Individual symptoms still deserve attention. 1 2

Does Zepbound cause depression?

No increased population-level risk was found in the FDA review. Zepbound's warning was removed in February 2026. That does not prove Zepbound cannot be part of one person's mood change, so report new or worsening symptoms. 1 3

Can GLP-1 medicines cause anxiety?

The FDA review and randomized meta-analyses did not find an overall increase in anxiety. A 2026 observational study did find more anxiety diagnoses after GLP-1 treatment ended, but it did not prove withdrawal or causation. 1 8 20

Why does my Medication Guide still show a suicide warning?

It may be an older printed version. Check the current label on DailyMed and look at "Recent Major Changes." Wegovy, Zepbound, and Saxenda all now show the section as removed. 3 4 5

Can semaglutide cause emotional numbness or anhedonia?

Emotional numbness has not been established as a predictable semaglutide effect. Anhedonia means loss of interest or pleasure. If it is new, persistent, or affecting daily life, do not dismiss it because a large study was reassuring. Contact your prescriber.

Can I take a GLP-1 with an antidepressant?

Often, but the answer depends on the exact medicine. Current labels do not list a blanket antidepressant contraindication. They do warn that delayed stomach emptying can affect oral medicines. Lithium deserves a specific monitoring plan because toxicity cases have been published. 2 3 17 18

Should I stop my GLP-1 if my mood drops?

Do not change it on your own; contact the prescriber promptly. A clinician may discuss delaying an increase, lowering a dose, treating dehydration or low intake, pausing, switching, or treating depression directly. If you may hurt yourself or cannot stay safe, call or text 988 now or use emergency care.

Can GLP-1 medicines help depression?

No GLP-1 is approved to treat depression. Some observational and early randomized findings are interesting, but they do not justify starting a GLP-1 as an antidepressant or replacing proven depression treatment. 12 19

Is depression a contraindication for GLP-1 medications?

No. Depression is not listed as a contraindication for Wegovy or Zepbound. It should still be disclosed so the prescriber can screen, plan follow-up, and review your full medication list. 2 3

What if my symptoms started right after a dose increase?

Write the date down and call the prescriber. Timing matters, but it is not proof. Dose changes can also affect nausea, eating, fluids, sleep, blood sugar, and oral medicines.

Will a telehealth program turn me down if I mention depression?

Depression alone is not a labeled contraindication. A program may need more history or may decide that in-person care is safer in a complex or urgent situation. A program that asks about mental health is doing better screening than one that asks nothing.

Should I report a mood change to the FDA?

You can. Patients and clinicians can submit reports through FDA MedWatch. A report does not prove the medicine caused the event, but it helps regulators look for patterns. 1

Where can I get help right now?

In the U.S., call or text 988. The Suicide & Crisis Lifeline is free and available 24 hours a day. You do not have to be suicidal to use it. Call 911 or go to an emergency room if danger is immediate. 24

The bottom line

The population evidence is reassuring. Ninety-one trials, 107,910 people, and no signal. Plus more than 2.2 million people in a separate FDA study. The warning came from weight-loss labeling precedent and was removed after the evidence review.

None of that requires you to ignore what you're feeling.

Both things are true at once: the drug is not raising depression risk across the populations studied, and something real may be happening to you. The way through isn't picking a side of the internet. It's getting specific — what changed, when it changed, what else was going on, and who can actually help.

Write down your dates. Make one call. Take the note with you.

📋 Two minutes now can save you a wasted appointment

Build my GLP-1 mood timeline →

Free. No email. Nothing stored. It organizes your dose dates, symptoms, food, fluids, sleep, and medication changes into a note your prescriber can read quickly.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Handle any urgent mood concern first. The quiz compares program fit — it does not diagnose depression or replace medical care.

Related reading

• GLP-1 contraindications and screening
• Is compounded semaglutide safe?
• What is a GLP-1?
• Compare highly rated GLP-1 providers

Sources

Regulatory and labels

1. U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications. January 13, 2026.
2. Novo Nordisk. Wegovy Prescribing Information. Current revision checked August 6, 2026.
3. U.S. Food and Drug Administration. Zepbound Prescribing Information, label 217806s042. Revised February 2026.
4. U.S. Food and Drug Administration. Saxenda Prescribing Information, label 206321s024. Revised February 2026.
5. National Library of Medicine. DailyMed: Wegovy. Current label checked August 6, 2026.

Mental-health evidence

6. Pierret ACS, Mizuno Y, Saunders P, et al. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82(7):643-653. doi:10.1001/jamapsychiatry.2025.0679.
7. Wadden TA, et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of STEP 1, 2, 3, and 5. JAMA Internal Medicine. 2024;184(11):1290-1300. doi:10.1001/jamainternmed.2024.4346.
8. Han J, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(6):5011-5019. doi:10.1111/dom.70692.
9. Tang H, Lu Y, Donahoo WT, et al. GLP-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes: A Target Trial Emulation Study. Annals of Internal Medicine. 2025;178(3):315-326.
10. Chang Y, Hsieh MH, Ju PC, Chang CC. Risk of Depression With GLP-1 Receptor Agonists Use in Overweight or Obese Adults With Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2026;28(1):197-209. doi:10.1111/dom.70175.
11. Kornelius E, et al. The Risk of Depression, Anxiety, and Suicidal Behavior in Patients With Obesity on GLP-1 Receptor Agonist Therapy. Scientific Reports. 2024;14:24433.
12. Taipale H, Taylor M, Lähteenvuo M, et al. Association Between GLP-1 Receptor Agonist Use and Worsening Mental Illness in People With Depression and Anxiety in Sweden. The Lancet Psychiatry. 2026;13(4):327-335.
13. Bushi G, et al. Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis. Diabetes & Metabolism Research and Reviews. 2025;41(2):e70037. doi:10.1002/dmrr.70037.
14. European Medicines Agency. Acomplia (rimonabant): EU Authorization Withdrawn. January 2009.
15. U.S. Food and Drug Administration. Contrave Prescribing Information.
16. U.S. Food and Drug Administration. Qsymia Prescribing Information, label 022580s029.
17. Al-Soleiti M, Leung JG, Mubaydeen T, et al. Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review. Journal of Clinical Psychopharmacology. 2025;45(6):613-618.
18. Lithium Toxicity Following a Change From Semaglutide to Tirzepatide for Weight Loss Management. Mental Health Clinician. 2026;16(1):34-38.
19. Gill H, Badulescu S, Shah H, et al. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(7):751-754. doi:10.1001/jamapsychiatry.2026.0594.
20. Zhang X, He Q, Ning J, et al. Association of GLP-1RA Discontinuation and Risk of Depressive and Anxiety Disorders in People With Type 2 Diabetes: A Cohort Study. Nature Metabolism. 2026. doi:10.1038/s42255-026-01567-z.
21. U.S. Food and Drug Administration. FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. Updated June 15, 2026.
22. Wilding JPH, et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism. 2022.
23. ClinicalTrials.gov and U.S. Food and Drug Administration. SURMOUNT-1 protocol I8F-MC-GPHK and Wegovy clinical review, including STEP 1 protocol NN9536-4373.
24. 988 Suicide & Crisis Lifeline. Accessed August 6, 2026.